Metabolic Cofactor

NAD+ / NMN

Promising preclinical data with emerging human trial evidence.

Sirtuin pathway (SIRT1–7)PARP DNA repairNAMPT/NAD+ salvagePGC-1α mitochondrial biogenesis

71 B

Evidence Score

ⓘ For informational purposes only — not medical advice.

Score Breakdown

Overview

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are NAD+ precursors being investigated for anti-aging and metabolic health. While preclinical data is robust, human clinical trial evidence is still emerging. Several small RCTs have been published, but large-scale definitive trials are lacking.

Mechanism of Action

NMN is converted to NAD+ via the salvage pathway enzyme NMNAT. NAD+ serves as a cofactor for sirtuins (SIRT1-7), PARPs (DNA repair), and CD38. Sirtuin activation drives mitochondrial biogenesis (PGC-1α), oxidative stress resistance, and epigenetic regulation through histone deacetylation.

Evidence Base

Multiple small human RCTs (n=25–80) have demonstrated NAD+ level increases with NMN/NR supplementation. The MIB-626 trial showed improved insulin sensitivity. However, no large Phase III trials exist, and FDA approval has not been pursued for any therapeutic indication. NMN's regulatory status as a supplement vs. investigational drug remains contested.

Gene Pathway Detail

NAD+ replenishment activates sirtuin-mediated gene regulation: SIRT1 deacetylates PGC-1α to promote mitochondrial biogenesis, SIRT3 regulates mitochondrial protein acetylation, and SIRT6 modulates DNA repair gene expression. Biomeme can monitor sirtuin pathway activation and mitochondrial gene expression to assess whether NAD+ supplementation is producing functional molecular changes.

mRNA Monitoring Insight

mRNA monitoring of sirtuin targets and mitochondrial biogenesis genes provides molecular evidence of NAD+ pathway engagement. This is particularly valuable for NAD+ precursors because serum NAD+ levels are difficult to measure clinically, and gene expression changes may be the most accessible biomarker of functional response.

Safety Considerations

Generally well-tolerated in published studies. No serious adverse events reported in human trials to date. However, long-term safety data is limited. Theoretical concerns exist around PARP activation in cancer biology. Not FDA-approved for any indication.

FAQ

Does NMN actually work?

Preclinical evidence is strong, and small human studies show NAD+ level increases and some metabolic benefits. However, the human evidence base is still emerging, and definitive large-scale trials have not been completed. This is reflected in the B grade.

Quick Facts

Category: Metabolic Cofactor
Score: 71/100 (B)
Gene Pathways: 4 characterized

Sources

[1] NMN Human Trial — Science 2022

Compare Others

Monitor Your Peptide Response.

Biomeme's transcriptomic platform tracks molecular pathway engagement so you know if your therapy is working.